Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

Author: Benzinga Newsdesk | December 04, 2023 10:57am

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.

Posted In: GDTC